Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey
Authors:
Open Access
- 21 November 2007
- journal article
- research article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 62 (1) , 18-26
Abstract
Benign prostatic hyperplasia (BPH) is a bothersome disease that can progress if left untreated. However, patient and urologist perspectives on BPH management are not fully understood. The aim of the Prostate Research on Behaviour and Education (PROBE) Survey was to assess healthcare-seeking behaviour and attitudes to BPH treatment in 502 BPH patients, and the beliefs and management practices of 100 urologists, from France, Germany, Italy, Spain and the UK. The principal concerns of patients seeking medical advice were fear of cancer, sleep disruption, discomfort or embarrassment. The majority of BPH patients recalled receiving a digital rectal examination (61%), routine prostate-specific antigen (PSA) tests (67%) and prescription medication (72%). Eighty per cent of 5alpha-reductase inhibitor (5ARI) users vs. 68% of alpha-blocker users were satisfied with their treatment. More than half of the patients were concerned about requiring surgery or developing acute urinary retention, and >75% would prefer a drug that provides reduction in the risk of surgery than one that provides rapid symptom relief. Most urologists performed digital rectal examinations (96%) and PSA tests (71%) on >90% of patients presenting with BPH symptoms. Eighty-seven per cent of urologists believe that BPH progresses, and 78% believe that 5ARIs prevent BPH progression. However, most urologists prescribe alpha-blockers while few prescribe 5ARIs. This study highlights discrepancies between views and beliefs of patients and physicians regarding BPH and current practice in Europe.Keywords
This publication has 16 references indexed in Scilit:
- Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at riskBJU International, 2007
- Therapeutic Strategies for Managing BPH ProgressionEuropean Urology Supplements, 2006
- BPH: Social Impact and Patient's PerspectiveEuropean Urology Supplements, 2006
- Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey*International Journal Of Clinical Practice, 2006
- Long‐term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α‐reductase inhibitor dutasteride: results of 4‐year studiesBJU International, 2005
- The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its managementBJU International, 2004
- Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2004
- The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic HyperplasiaNew England Journal of Medicine, 2003
- Introduction and Concluding RemarksEuropean Urology, 1999
- Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond.Journal of Clinical Pathology, 1996